Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xynomic Completes Pre-IND Conference with US FDA for RAF Inhibitor

publication date: Jun 12, 2019

Xynomic, a US-China oncology pharma, recently completed a pre-IND meeting with the US FDA for its pan-RAF inhibitor XP-102. It said the FDA provided valuable advice on its clinical development plan for the candidate. The company, which thinks XP-102 may prove to be best-in-class, hopes to file for XP-102 in the second half of 2019. In 2017, Xynomic announced a $502 million agreement to acquire global rights to the molecule from Boehringer Ingelheim. More details...

Stock Symbol: (NSDQ: XYN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here